Home / About Peptonic

About Peptonic

PEPTONIC medical is developing an estrogen-free treatment for vaginal atrophy. The patented product is based on local, vaginal application of oxytocin.

Our vision is to make the naturally occurring hormone, oxytocin, the leading treatment for women suffering from vaginal atrophy during menopause and after.

To date, four clinical studies have been performed. Three of these were randomized, double-blind and placebo controlled. The studies have shown positive effects of the new oxytocin based treatment on local signs of vaginal atrophy within the vaginal wall and a reduction of bothersome symptoms.

In July 2014, PEPTONIC medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm. The current number of shareholders is approximately 250. One of them is Professor Kerstin Uvnäs Moberg, who is the person who discovered and charted the possibility of using oxytocin for the treatment of vaginal atrophy.


Contact us

Please contact us if you would like to know more about PEPTONIC medical or Vagitocin®.

Contacts »

Subscribe for press releases

Would you like to receive press releases and news from PEPTONIC Medical straight to your email? Register for our newsletter service on aktietorget.se.

Subscribe for press releases and news »